FANCL缺陷易致内皮损伤:肺动脉高压的新治疗靶点
研究通过Fancl基因敲除小鼠、AAV-Fancl过表达模型及患者肺组织与肺动脉内皮细胞,发现特发性肺动脉高压患者内皮细胞FANCL显著下调;Fancl缺陷小鼠自发PAH并对丝裂霉素C诱导的PAH易感,AAV-Fancl或氨磷汀可逆转表型。
要点
- 特发性肺动脉高压患者内皮细胞FANCL表达显著下调。
- Fancl缺陷小鼠自发PAH且对烷化剂诱导PAH易感。
- AAV-Fancl补充或氨磷汀可 rescue 病理表型。
核心结论
- Fancl缺陷通过加重DNA损伤和凋亡促进肺动脉高压发生。
- 靶向补充Fancl是治疗肺动脉高压的潜在新策略。
研究设计与样本
- 使用Fanclkf/kf敲除优先小鼠模型和AAV9介导的Fancl过表达模型。
- 分析患者肺标本、肺动脉内皮细胞及野型与Fanclkf/kf小鼠原代PMVECs。
- 纳入野型与Fanclkf/kf小鼠原代培养的肺微血管内皮细胞。
主要发现
- 肺单细胞RNA测序显示特发性PAH患者内皮细胞FANCL显著下调。
- 临床样本和野百合碱诱导PAH大鼠模型验证FANCL下调。
- Fanclkf/kf小鼠自发PAH并对丝裂霉素C诱导PAH易感,伴PMVECs严重DNA损伤和凋亡。
- Fanclkf/kf小鼠PMVECs中BMP信号受抑且TGF-β通路过度激活。
关键数值与推荐
- AAV-Fancl基因补充或氨磷汀药物干预可挽救Fanclkf/kf小鼠病理表型。
- AAV-Fancl治疗小鼠PMVECs中BMP/TGF-β信号失衡完全恢复。
临床怎么用
- FANCL表达下调可作为PAH内皮损伤的潜在生物标志物。
- 靶向恢复Fancl或使用DNA损伤保护剂氨磷汀可能成为PAH治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Clinical observations have suggested an association between alkylating agent-based chemotherapy and pulmonary arterial hypertension (PAH). The Fanconi anemia (FA) pathway, the principal mechanism for resolving alkylating agent-induced DNA damage, has been implicated in this process. Objectives: To establish the interplay among the FA pathway, DNA damage, and PAH. Methods: A knockout-first mouse model for FA complementation group L (Fanclkf/kf) and an adenovirus-associated virus 9-mediated Fancl overexpression (AAV-Fancl) model were used. Lung specimens, pulmonary arterial endothelial cells from patients with PAH, and primarily cultured pulmonary microvascular endothelial cells (PMVECs) from wild-type and Fanclkf/kf mice were analyzed. Measurements and Main Results: Data analysis on lung single-cell RNA-sequencing datasets revealed significant downregulation of FANCL in endothelial cells from patients with idiopathic PAH, a finding consistently validated in both clinical samples (lung specimens and pulmonary arterial endothelial cells) and the monocrotaline-induced PAH rat model. Notably, Fanclkf/kf mice developed spontaneous PAH and showed heightened susceptibility to alkylating agent (mitomycin C)-induced PAH, characterized by severe DNA damage and apoptosis in PMVECs. These pathological phenotypes were rescued through Fancl gene supplementation via AAV-Fancl or pharmacological intervention with the DNA damage protector amifostine. Mechanistically, transcriptomic profiling combined with functional validation demonstrated a suppressed bone morphogenetic protein signaling coupled with hyperactivated transforming growth factor-β pathways in PMVECs from Fanclkf/kf mice. Importantly, this imbalance was fully restored in PMVECs from AAV-Fancl-treated mice. Conclusions: Deficient Fancl plays a key role to promote PAH, and targeted rescue of Fancl could be a novel effective strategy for the treatment of PAH.
引用
- Liu S, Shan X, Sun Y, et al. Deficient FANCL Predisposes to Endothelial Damage: A New Therapeutic Target for Pulmonary Hypertension. Am J Respir Crit Care Med. 2025. PMID: 40479584. doi:10.1164/rccm.202408-1655OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。